Childhood spinal muscular atrophy.
Anterior horn cell
Disease-modifying therapy
Motor neuron disease
SMN1 gene
Spinal muscular atrophy
Journal
Handbook of clinical neurology
ISSN: 0072-9752
Titre abrégé: Handb Clin Neurol
Pays: Netherlands
ID NLM: 0166161
Informations de publication
Date de publication:
2023
2023
Historique:
medline:
28
8
2023
pubmed:
25
8
2023
entrez:
24
8
2023
Statut:
ppublish
Résumé
Spinal muscular atrophy (SMA) is caused by biallelic mutations in the SMN1 (survival motor neuron 1) gene on chromosome 5q13.2, which leads to a progressive degeneration of alpha motor neurons in the spinal cord and in motor nerve nuclei in the caudal brainstem. It is characterized by progressive proximally accentuated muscle weakness with loss of already acquired motor skills, areflexia and, depending on the phenotype, varying degrees of weakness of the respiratory and bulbar muscles. Over the past decade, disease-modifying therapies have become available based on splicing modulation of the SMN2 with SMN1 gene replacement, which if initiated significantly modifies the natural course of the disease. Newborn screening for SMA has been implemented in an increasing number of centers; however, available evidence for these new treatments is often limited to a small spectrum of patients concerning age and disease stage.
Identifiants
pubmed: 37620083
pii: B978-0-323-98817-9.00030-2
doi: 10.1016/B978-0-323-98817-9.00030-2
pii:
doi:
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
43-58Informations de copyright
Copyright © 2023 Elsevier B.V. All rights reserved.